54024-22-5 Usage
Description
Desogestrel is a synthetic progestogen. It inhibits ovulation and prevents fertilization in rabbits and mice. Desogestrel inhibits rhodamine 123 efflux, a measure of P-glycoprotein activity, ex vivo in human lymphocytes and CD8+ T cells in a dose-dependent manner. Formulations containing desogestrel have been used as oral contraceptives and for the treatment of polycystic ovary syndrome.
Chemical Properties
White Solid
Originator
Dicromil,Organol ,W. Germany,1981
Uses
A progestogen with low androgenic potency
Manufacturing Process
A solution of 1.0 g of 11,11-methylene-18-methyl-delta4-estren-17-one in 33
ml tetrahydrofuran was added to a potassium-acetylide solution in
tetrahydrofuran.
After 2 hours of stirring at 0°C to 5°C the reaction mixture was acidified with
2N H2SO4and processed further.By a chromatographic treatment on silica gel and crystallization from pentane
0.7 g of 11,11-methylene-17α-ethynyl-18-methyl-δ4-estren-17β-ol with a
melting point of 109°C to 110°C and an [α]D of +55°C (CHCl3) was obtained.
Therapeutic Function
Progestin
General Description
Desogestrel, (17α)-13-ethyl-11-methylene-18,19-dinorpregn-4-en-20-yn-17-ol, is a 19-nortestosterone analog with good progestin activity. Likethe other progestins, it is orally active and used in combinationwith an estrogen in oral contraceptives. Desogestrel is aprodrug that must be oxidized to the 3-one in vivo to haveprogestational action. CYPs 2C9 and 2C19 have been implicatedin the initial hydroxylation of desogestrel at C3.
Clinical Use
Desogestrel also is a prodrug and is rapidly metabolized in the intestinal mucosa and on first pass through the liver to its active metabolite, etonogestrel (3-ketodesogestrel). Following oral administration, the relative bioavailability for desogestrel is approximately 84%. Desogestrel also exhibits high selectivity for the progesterone receptor and low and rogenic activity, and it does not diminish the beneficial effects of estrogen on the lipid profile.
Check Digit Verification of cas no
The CAS Registry Mumber 54024-22-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,4,0,2 and 4 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 54024-22:
(7*5)+(6*4)+(5*0)+(4*2)+(3*4)+(2*2)+(1*2)=85
85 % 10 = 5
So 54024-22-5 is a valid CAS Registry Number.
InChI:InChI=1/C22H30O/c1-4-21-14-15(3)20-17-9-7-6-8-16(17)10-11-18(20)19(21)12-13-22(21,23)5-2/h2,8,17-20,23H,3-4,6-7,9-14H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
54024-22-5Relevant articles and documents
Base promoted air oxidation of 13β-ethyl-11-methylenegon-4-en-17-one
Compostella, Federica,Colombo, Diego,Modica, Emilia,Antonio Scala,Toma, Lucio,Bovio, Bruna,Ronchetti, Fiamma
, p. 111 - 117 (2002)
The structure of 13-ethyl-11-methylene-18,19-dinor-17α-pregn-4-en-20-yn-16β,17-diol (3, 16β-OH desogestrel), a by-product obtained in the last step of the synthesis of desogestrel (1) by reaction of monolithium acetylide-ethylenediamine complex with 13β-e
Intermediate used for synthesis of desogestrel, and preparation method and application thereof
-
Paragraph 0062; 0063; 0064; 0065; 0066, (2016/10/08)
The invention discloses an intermediate used for synthesis of desogestrel, and a preparation method and application thereof. The intermediate has a general chemical structural formula as described in the specification, wherein a substituting group R is selected from the group consisting of hydrogen, methyl or ethyl. The intermediate is prepared by subjecting a compound as shown in a formula 2 to selective protection reaction for a 3-carbonyl group by using dihydric alcohol, wherein the dihydric alcohol has a chemical structural formula as described in the specification, wherein R is selected from the group consisting of hydrogen, methyl or ethyl; and a reaction formula of the dihydric alcohol is described in the specification. The method for the synthesis of the desogestrel by employing the intermediate comprises a reaction route as described in the specification.
Desogestrel preparation method and midbody compound
-
Paragraph 0057; 0058; 0059; 0060, (2016/10/17)
The invention relates to a novel steroidal compound and application of the novel steroidal compound in a desogestrel preparation process. The novel compound easy to separate is obtained through 17-bit selective ethynylation of 13beta-ethyl pregnane-4, 5-alkene-11, 17-diketone. When the compound is used for preparing desogestrel, simplicity and convenience in operation are achieved, and yield is high.